Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
Jian Li(Beijing Normal University), Lin Shen(Peking University), Yanhong Deng(Sun Yat-sen University), Shirong Cai(Sun Yat-sen University), Yongjian Zhou(First Affiliated Hospital of Zhengzhou University), Hui Cao(Huainan Normal University), Juan Dong(Shanghai Chengtou (China)), Xin Wu(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhao Huang(Sichuan University), Jun Zhang(The Affiliated Yongchuan Hospital of Chongqing Medical University), Ye Zhou(Second Military Medical University)
Cited by 15
Related Papers
Systemic immune-inflammation index for predicting prognosis of colorectal cancer
|World Journal of Gastroenterology|2017|736
Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis
|JNCI Journal of the National Cancer Institute|1999|558
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
|Clinical Cancer Research|2018|456